Thu, Jul 10, 2014, 7:07 AM EDT - U.S. Markets open in 2 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

bionerd51 144 posts  |  Last Activity: Jul 8, 2014 9:16 AM Member since: Jan 2, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Adam F. has a good article on these recycled reports on eteplirsen's putative declining efficacy. Bottomline: it revolves around the 2 twins that were eliminated from treatment/placebo population from analysis due to decline BEFORE treatment began to have effects [24-36 weeks].

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 27, 2014 8:22 AM Flag

    In SA reporting that Isis's entire 2.0 2MOE platform will have exact toxicity profile as Kynamro. Ouch!..I've been reporting this for over a decade. Don't expect Wall Street to abandon Stan Crooke…Snake Oil salesman

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Jun 23, 2014 1:55 PM Flag

    The European regulatory bodies {MHRA] for drug and biologics will not approve an application without a lawful patent. They might change their minds if approved by the FDA in the U.S. first and if Sarepta can prove that Eteplirsen is a safer and more efficacious drug compared to Drisa.

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 23, 2014 12:35 PM Flag

    Although there is not a lot written on SRPT's PMO-X program maybe I can shed some light on what specific homing peptide they are using. SRPT's early research in this area of enhanced PMO delivery was in a chimeric peptide which is a combination delivery peptide and muscle specific peptide. The resul;ts were mixed and they discovered that most of this chimeric was ending up in the liver. An improved muscle specific peptide [homing] I believe they are using a 12-mer peptide, M12. It is safe up to 75mg/kgs, it restores 25% of dystrophin in skeletal muscles and very little ends up in the liver. The exact amino acid/polypeptide composition I do not know but it looks like a significant improvement over the PPMO and PMO.

    Sentiment: Strong Buy

  • The ebola outbreak in Western Africa has reach alarming numbers. Anyone can access article[s] on web. I still believe SRPT's ebola antiviral [2 or 3 targets] is better than the competition. This is a real failure of the Bioshield law and DOD.

    Sentiment: Strong Buy

  • Reply to

    Will there be an Isis - Sarepta SMA battle?

    by copphiggins Jun 17, 2014 10:18 AM
    bionerd51 bionerd51 Jun 17, 2014 12:48 PM Flag

    Hong Moulton, biochemist and formerly of AVII was pursuing different conjugated peptide delivery systems coauthored an SMA paper using naked PMO's and Octaguanine[GeneTools] assisted PMO's . Both rescued SMA phenotype via various delivery pathways. I'm convinced based on 18 years of studying this specific oligo field that the PMO will outperform Isis's 2'OME/MOE in this pathology. SRPT is at advantage for this target because of safety, stability and a more efficient W/C binding affinity. Factor Iversen's lab work on manipulating nitrogen bases like guanine-cyto. and adenine-thymine.in translocation of the BBB.

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Jun 13, 2014 12:16 PM Flag

    Jon, I agree with Summerton on oligo cancer targeting. One must target several gene onco transcripts at the same time. One target oligo therapies are doomed to fail. One exception..if one could administer high doses of S-DNAs the toxicity alone might kill cancer cells. I heard Jim was pursuing this area of cancer Tx. [poly-targeting]

    Sentiment: Strong Buy

  • Reply to

    Irrational exuberance about 144 week results?

    by berrybill725 Jun 12, 2014 8:23 AM
    bionerd51 bionerd51 Jun 13, 2014 9:10 AM Flag

    The key to approval under accelerated review/Orphan Drug in this case is that the 10 pts. continue to remain in the stat. sign. zone and the 2 removed [mITT] that were removed from total treatment cohort population is consistent with SRPT's hypothesis that the treatment kicked in to late based on age with these 2 patients and that trend continues in PhaseIII trial data based on similar age and body type. [run on sentence]

    Sentiment: Strong Buy

  • Reply to

    ISIS stock price just moved above SRPT

    by whatmeworriee Jun 10, 2014 10:34 AM
    bionerd51 bionerd51 Jun 10, 2014 12:10 PM Flag

    Love, I have to strongly disagree with you. At therapeutic PMO levels there has been no adverse advents, elevate of liver enzymes which occur daily with the S-DNA's. The only reported toxicity in animal studies that I have seen is when 100X's expected therapeutic dose PMO will accumulate in certain organs and reports of mild granulation in kidneys. By far the safest Oligo in development todays. Only oligo that can be used in live zebrafish for knockdown and up regulation studies. There are more uses in animal models that I won't get into today.

    Sentiment: Strong Buy

  • Reply to

    starfe

    by redlaw9 Jun 8, 2014 11:02 PM
    bionerd51 bionerd51 Jun 9, 2014 11:09 AM Flag

    TKMR's chemistries have very little chance of succeeding in a PhaseIII trial. One could ride the biotech run but once it corrects, watch out TKMR shareholders

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Jun 6, 2014 8:47 AM Flag

    Journal article highlights the new novel approaches of treating DMD. Eterplirsen rates the most promising. Can't post link but you can access at Current Pediatrics or PUBMED.

    Sentiment: Strong Buy

  • Reply to

    Top line data

    by lou_mangini Jun 5, 2014 8:44 AM
    bionerd51 bionerd51 Jun 5, 2014 11:24 AM Flag

    Micro, I believe this is the first time SRPT has paid to be a top-level sponsor of a Confab. This sounds like very good data will be presented. If not why would they take such a high-profile position in a broker sponsored conference.

    Sentiment: Strong Buy

  • Reply to

    Comparison of Morpholino and 2'-O-Me oligos

    by jonmoulton Jun 3, 2014 5:14 PM
    bionerd51 bionerd51 Jun 4, 2014 1:50 PM Flag

    The chemical characteristics of the PMO have out performed the S-DNA's since the 1990's in organisms, nonhuman primates and as antivirals and antibacterials. The only people who do not know this is the brokerages that follow ISIS and WallStreet

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 May 19, 2014 12:02 PM Flag

    In SA re: Isis and Stan Crooke's BullXXXX. It's amazing what WallStreet will fall for. This is exactly why no one should take oligo advice/ investing biotech from RNAianalyst, a/k/a Dirk H.

    Sentiment: Strong Buy

  • Reply to

    missense therapy

    by musherga May 7, 2014 12:21 PM
    bionerd51 bionerd51 May 7, 2014 12:31 PM Flag

    Another name associated with these types of mutations are polymorphs.

  • Reply to

    missense therapy

    by musherga May 7, 2014 12:21 PM
    bionerd51 bionerd51 May 7, 2014 12:29 PM Flag

    A single "base pair" mutation changes one amino acid in a polypeptide. One base can be skipped over to correct a diseased protein.

  • bionerd51 bionerd51 May 7, 2014 9:57 AM Flag

    While I agree with your comments that the known data for eteplirsen is NDA quality, I personally would like to see another biopsy. If my hypothesis is correct and the primary uptake of PMO [all oligos] is via myocytosis in the 3 major muscle groups then a biopsy 2 years post- drug initiation should reveal outstanding dystrophin production and incorporation into functional complexes that will seal the deal for a positive NDA outcome. This will benefit all DMD patients, present and future and would support future class-like approval for rare exonic DMD boys.

    Sentiment: Strong Buy

  • Reply to

    Another S-DNA Failure...

    by bionerd51 Apr 29, 2014 1:27 PM
    bionerd51 bionerd51 Apr 30, 2014 2:26 PM Flag

    likeafox, The EU patent office, in a hometown ruling, gave Prosensa the patent for exon 51 based on a broad definition of all oligonucleotides against a specific target, exon 51. They were awarded exon51 because they felt Ryzard Kole [co-founder with Sidney Altman of exon-skipping process] patent filing was too broad and was about to expire [all oligos] while Prosensa's researcher was more specific in language. It was a strange ruling and the Kole patent predated the Dutch researcher's claim but this was a clear home court ruling. Appeal is still ongoing but this could all be mute if eteplirsen comes to market first and it can be proven to be superior to Drisa.

    Sentiment: Strong Buy

  • Reply to

    Sarepta is the number one Company for the future

    by usagary1 Apr 30, 2014 10:12 AM
    bionerd51 bionerd51 Apr 30, 2014 10:17 AM Flag

    Gary, Smart biotech money is starting to realize that SRPT is only game in town.

  • Reply to

    Isis Getting Hammered...

    by bionerd51 Apr 30, 2014 9:51 AM
    bionerd51 bionerd51 Apr 30, 2014 10:14 AM Flag

    Stanley Crooke is a con man. He has Wall Street believing that their chemistry is better than ice-cream. Anyone with half a brain knows differently. Today's PR proves that. Sarepta is the only antisense company that has great future potential.

    Sentiment: Strong Buy

TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gigamon Inc.
NYSEWed, Jul 9, 2014 4:04 PM EDT
Alaska Air Group, Inc.
NYSEWed, Jul 9, 2014 4:02 PM EDT